Genentech’s request was well above Roche’s $89-a-share offer in July and one the Swiss pharmaceutical giant rejected as too expensive, documents filed by Roche say.
More: continued here
Genentech’s request was well above Roche’s $89-a-share offer in July and one the Swiss pharmaceutical giant rejected as too expensive, documents filed by Roche say.
More: continued here